How to Improve your Primary Cell Analysis: Make it Accurate, Quick and Simple

This webinar takes a look at primary cell analysis and the difficulties of counting with traditional methods and presents an alternative of fluorescent counting.

By |2018-11-02T17:46:33+00:00November 1st, 2018|Categories: Video|Tags: , , , |0 Comments

Do you rely on a Flow Cytometer? Want to break free?

If you rely on a flow cytometer in a core lab or a central facilities lab, have you ever wondered if there was a better way? Have you ever wished to have full control over your experiments, rather than hand your sample over to a technician?  There was an interesting article written recently about the needs of researchers. Have you seen this? Those interviewed for the article suggest that there are some main factors for consideration: The instrument size needs a smaller footprint than existing products offer The price of the instrument should be under $100,000 Software ease-of-use to reduce [...]

By |2017-02-15T11:25:08+00:00February 15th, 2017|Categories: About Cell-Based Assays|Tags: , |0 Comments

Cellometer Vision tracks apoptosis in embryonic neural stem cells after propofol exposure

Introduction Propofol, a widely used general anesthetic, has been shown to produce neurotoxicity in neonatal animal experiments [1-5]. The possible detrimental effects of anesthetics, particularly in developing brains, require further study, as recent studies suggest that general anesthesia given to children younger than four years of age can increase the chances of learning disabilities later in life [6]. Here, researchers used embryonic neural stem cells to investigate the neurotoxic effects of propofol in vitro. Materials and Methods Cell culture and drug exposure Embryonic neural stem cells were collected from embryonic day 16 Sprague-Dawley rats. Resulting cells were cultured in 96-well [...]

Cellometer Vision CBA image cytometry reveals the utility of the immunocompetent mouse model “Glowing Head” in assessing preclinical anti-tumor therapies

Introduction Preclinical models to evaluate therapeutic efficacy in the area of oncology have proven to be a challenge. The standard of preclinical assessment as always been immunosuppressed mice, but that model has not reliably predicted clinical efficacy [1]. Immunocompetent genetically engineered mice with tumor allograft models seem more promising, and yet reporter tags such as GFP and luciferase are targeted by competent immune systems, which may interfere with tumor growth and the response to therapeutics. Here, a collaborative group of researchers has created a reporter-tolerized genetically engineered mouse model, dubbed “Glowing Head” (GH), by targeting a luciferase-GFP reporter into the [...]

Go to Top